Furthermore, IL-6 levels exceeded the threshold (3.8 pg/mL) in 82% (9/11) of patients with NB and in 44% (11/25) of patients with CIS, but only in 18% (3/17) of patients with MS. The gene discussed is IL6; the disease is in situ carcinoma.